US2022348618A1PendingUtilityA1

Compositions and methods of using islet neogenesis peptides and analogs thereof

Assignee: SHENZHEN HIGHTIDE BIOPHARMACEUTICAL LTDPriority: Mar 15, 2013Filed: May 18, 2022Published: Nov 3, 2022
Est. expiryMar 15, 2033(~6.6 yrs left)· nominal 20-yr term from priority
C07K 14/4733C07K 7/02A61P 29/00C07K 14/4738A61K 38/00A61P 5/48A61P 25/00C07K 7/08C07K 14/4705A61P 3/08C07K 14/475A61P 1/16A61P 3/10
80
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides peptides and analogs of INGAP and HIP peptides. The peptides and analogs can be used in methods for treating various diseases and conditions. Such diseases and conditions can include impaired pancreatic function, treating a metabolic disease, for example, diabetes, both type 1 and type 2 diabetes, islets induction, expansion and proliferation for transplantation, promoting neuroprotection or nerve regeneration, promoting liver regeneration or inhibiting inflammation.

Claims

exact text as granted — not AI-modified
1 - 50 . (canceled) 
     
     
         51 . A method for inhibiting inflammation, comprising administering to a subject in need thereof a peptide or analog thereof selected from the group consisting of SEQ ID NOs: 6, 8, 17-27, 32-40, 54-59, 63-67 and 75-110. 
     
     
         52 . The method of  claim 51 , wherein the peptide or analog thereof consists of a peptide or analog selected from the group consisting of SEQ ID NOs: 6, 8, 18-27 and 56-59. 
     
     
         53 . The method of  claim 51 , wherein the peptide or analog thereof is selected from the group consisting of SEQ ID NOs: 54, 55 and 63-67. 
     
     
         54 . The method of  claim 51 , wherein the peptide or analog thereof is selected from the group consisting of SEQ ID NOs: 17, 32-40 and 75-110.

Join the waitlist — get patent alerts

Track US2022348618A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.